Search
Cullinan Therapeutics Inc
CGEMAdd to Watchlist
21.080USD
-0.280-1.31%
Close 09-18 16:00（ET）
1.36BMarket Cap
LossP/E TTM
After-hours 16:13 (ET)20.540USD-0.510-2.42%
After-hours 16:13 (ET)Cullinan Therapeutics Inc (CGEM) Stock Price Target & Forecast
Analyst Rating
Based on 13 analysts giving stock ratings to Cullinan Therapeutics Inc in the past month.
Strong Buy
7 Strong Buy
6 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
36.667USD+78.51%
CGEM Analyst Recommendation Trends
In the current month, CGEM has received 6 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CGEM average Analyst price target in the last month is 36.667.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
7
7
7
7
7
5
5
5
6
6
6
6
6
6
6
6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13
13
13
13
13
11
11
11
CGEM Analyst Rating for Peer Comparison
Updated: Sep 18, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Ascendis Pharma A/S
ASND
10
10
0
0
0
20
Financial Forecasting
Based on analysts' estimates, CGEM EPS is projected to reach -0.849 in FY2026Q3, following reported EPS of -0.873 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.81
-0.83
-0.81
-0.85
-0.86
Actual
-0.86
-0.82
-0.87
--
--
Surprise
-5.83%
+0.89%
-7.85%
--
--
FAQs
What is Cullinan Therapeutics Inc's price target?
Analysts forecast that Cullinan Therapeutics Inc's price target is USD 36.67, with the highest forecast at USD 53.00 and the lowest forecast at USD 27.00.
How have Cullinan Therapeutics IncCGEM's recent earnings per share performed?
The market expectation was USD -0.87, while Cullinan Therapeutics IncCGEM's earnings per share (EPS) for the previous quarter was USD -0.82. EPS for the next quarter is expected at USD -0.85.
What is the analyst rating for Cullinan Therapeutics Inc?
Based on the ratings of Cullinan Therapeutics Inc's stock from 13 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.